BIONXT SOLUTIONS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4 CAD | +11.11% |
|
+1.27% | -17.53% |
| Apr. 26 | BioNxt Solutions Inc. Announces ODF Cladribine Update | CI |
| Apr. 26 | BioNxt Solutions Inc. announced that it expects to receive CAD 1.62 million in funding | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 46.99 | 116.4 | 83.87 | 53.81 | 52.06 |
| Enterprise Value (EV) 1 | 48.09 | 117.1 | 87.97 | 58.05 | 56.59 |
| P/E ratio | -5.66 x | -6.37 x | -3.68 x | -3.99 x | -6.24 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 225,774,379 x | 336,772,796 x | 292,725,520 x | 180,922,079 x | 139,864,918 x |
| EV / Revenue | 231,070,316 x | 338,879,171 x | 307,049,417 x | 195,159,524 x | 152,035,600 x |
| EV / EBITDA | -7.13 x | -8.11 x | -5.49 x | -9.06 x | -9.14 x |
| EV / FCF | -39.7 x | -23.2 x | -14.9 x | -12.5 x | -16.1 x |
| FCF Yield | -2.52% | -4.31% | -6.73% | -8.01% | -6.2% |
| Price to Book | 7.62 x | 29.3 x | 50 x | -13 x | -9.86 x |
| Nbr of stocks (in thousands) | 48,946 | 61,919 | 77,653 | 91,210 | 107,349 |
| Reference price 2 | 0.9600 | 1.880 | 1.080 | 0.5900 | 0.4850 |
| Announcement Date | 4/29/20 | 4/27/21 | 4/29/22 | 4/12/23 | 4/22/24 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | 0.2081 | 0.3457 | 0.2865 | 0.2974 | 0.3722 |
| EBITDA 1 | -0.7857 | -6.747 | -14.45 | -16.03 | -6.404 | -6.195 |
| EBIT 1 | -0.8548 | -7.086 | -14.7 | -16.21 | -6.574 | -6.36 |
| Operating Margin | - | -3,404.56% | -4,253.64% | -5,659.36% | -2,210.02% | -1,708.42% |
| Earnings before Tax (EBT) 1 | -0.8606 | -7.714 | -17.25 | -20.75 | -12.87 | -7.723 |
| Net income 1 | -0.8606 | -7.669 | -16.89 | -20.64 | -12.38 | -7.723 |
| Net margin | - | -3,684.77% | -4,886.32% | -7,203.23% | -4,160.84% | -2,074.68% |
| EPS 2 | -0.0378 | -0.1695 | -0.2952 | -0.2938 | -0.1477 | -0.0778 |
| Free Cash Flow 1 | -0.7088 | -1.212 | -5.05 | -5.922 | -4.65 | -3.507 |
| FCF margin | - | -582.16% | -1,461.1% | -2,066.93% | -1,563.42% | -942.08% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/27/19 | 4/29/20 | 4/27/21 | 4/29/22 | 4/12/23 | 4/22/24 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 1.1 | 0.73 | 4.1 | 4.23 | 4.53 |
| Net Cash position 1 | 1.32 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.1634 x | -0.0504 x | -0.2559 x | -0.6612 x | -0.7314 x |
| Free Cash Flow 1 | -0.71 | -1.21 | -5.05 | -5.92 | -4.65 | -3.51 |
| ROE (net income / shareholders' equity) | -22.1% | -109% | -327% | -727% | 1,006% | 164% |
| ROA (Net income/ Total Assets) | -11.6% | -50.4% | -108% | -113% | -72.5% | -276% |
| Assets 1 | 7.429 | 15.23 | 15.57 | 18.34 | 17.08 | 2.798 |
| Book Value Per Share 2 | 0.2000 | 0.1300 | 0.0600 | 0.0200 | -0.0500 | -0.0500 |
| Cash Flow per Share 2 | 0.0600 | 0.0100 | 0.0400 | 0.0200 | 0 | 0 |
| Capex 1 | 0.55 | 0.1 | 0.16 | 0.45 | 0 | 0.2 |
| Capex / Sales | - | 47.22% | 45.27% | 157.89% | 1.3% | 54.11% |
| Announcement Date | 3/27/19 | 4/29/20 | 4/27/21 | 4/29/22 | 4/12/23 | 4/22/24 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.53% | 32M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- BNXT Stock
- Financials BioNxt Solutions Inc.
